Survivin knockdown and concurrent 4-HPR treatment controlled human glioblastoma in vitro and in vivo

Neuro-Oncology

Volumn 12, Issue 11, 2010, Pages 1088-1101

  George, Joseph ^a   Banik, Naren L ^b   Ray, Swapan K ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

4 HPR; Glioblastoma; Intracerebral tumors; Survivin; U118MG; U251MG

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CASPASE 3; CASPASE 7; CASPASE 9; CD31 ANTIGEN; CYCLINE; CYTOCHROME C; FENRETINIDE; GELATINASE B; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLASMID DNA; SMALL INTERFERING RNA; SURVIVIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME RELEASE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR REGRESSION; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FENRETINIDE; GENE KNOCKDOWN TECHNIQUES; GENE THERAPY; GLIOBLASTOMA; HUMANS; IN SITU NICK-END LABELING; MICE; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650121259     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq079     Document Type: Article

References (36)

1. Ohgaki H. Epidemiology of brain tumors. Methods Mol Biol. 2009;472:323-342.
2. Drappatz J, Norden AD, Wen PY. Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev Neurother. 2009;9:519-534.
3. George J, Banik NL, Ray SK. Bcl-2 siRNA augments taxol mediated apoptotic death in human glioblastoma U138MG and U251MG cells. Neurochem Res. 2009;34:66-78.
4. George J, Gondi CS, Dinh DH, Gujrati M, Rao JS. Restoration of tissue factor pathway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis. Clin Cancer Res. 2007;13:3507-3517.
5. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008;14:5000-5005.
6. Sah NK, Khan Z, Khan GJ, Bisen PS. Therapeutic strategies for inhibiting invasion in glioblastoma. Cancer Lett. 2006;244:164-171.
7. Yamamoto H, Ngan CY, Monden M. Cancer cells survive with survivin. Cancer Sci. 2008;99:1709-1714.
8. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 2002;277:3247-3257.
9. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy. Expert Opin Ther Targets. 2008;12:463-476.
10. Sogno I, Venè R, Sapienza C, Ferrari N, Tosetti F, Albini A. Anti-angiogenic properties of chemopreventive drugs: fenretinide as a prototype. Recent Results Cancer Res. 2009;181:71-76.
11. Damodar Reddy C, Guttapalli A, Adamson PC, Vemuri MC, O'Rourke D, Sutton LN, et al. Anticancer effects of fenretinide in human medulloblastoma. Cancer Lett. 2006;231:262-269.
12. Simeone AM, Tari AM. How retinoids regulate breast cancer cell proliferation and apoptosis. Cell Mol Life Sci. 2004;61:1475-1484.
13. Tiwari M, Kumar A, Sinha RA, Shrivastava A, Balapure AK, Sharma R, et al. Mechanism of 4-HPR-induced apoptosis in glioma cells: evidences suggesting role of mitochondrial-mediated pathway and endoplasmic reticulum stress. Carcinogenesis. 2006;27:2047-2058.
14. Lovat PE, Corazzari M, Goranov B, Piacentini M, Redfern CP. Molecular mechanisms of fenretinide-induced apoptosis of neuroblastoma cells. Ann N Y Acad Sci. 2004;1028:81-89.
15. George J, Banik NL, Ray SK. Combination of taxol and Bcl-2 siRNA induces apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis, and tumour growth. J Cell Mol Med. 2009; 13:4205-4218.
16. George J, Tsutsumi M. siRNA-mediated knockdown of connective tissue growth factor prevents N-nitrosodimethylamine-induced hepatic fibrosis in rats. Gene Ther. 2007;14:790-803.
17. Tolboom TC, Huizinga TW. In vitro matrigel fibroblast invasion assay. Methods Mol Med. 2007;135:413-422.
18. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
19. Sckell A, Leunig M. Dorsal skinfold chamber preparation in mice. In: Murray, JC, ed. Angiogenesis Protocols: Methods in Molecular Medicine. Vol 46. Totowa, NJ: Humana Press; 2001:95-105.
20. Wachsberger PR, Burd R, Marero N, Daskalakis C, Ryan A, McCue P, et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res. 2005; 11:835-842.
21. Wang H, Maurer BJ, Liu YY, Wang E, Allegood JC, Kelly S, et al. N-(4-hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing. Mol Cancer Ther. 2008;7:2967-2976.
22. Sampath J, Pelus LM. Alternative splice variants of survivin as potential targets in cancer. Curr Drug Discov Technol. 2007;4:174-191.
23. Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol. 2006;18:609-615.
24. Chandele A, Prasad V, Jagtap JC, Shukla R, Shastry PR. Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia. 2004;6:29-40.
25. Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, et al. An antiapoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry. 2001;40:1117-1123.
26. Simeone AM, Ekmekcioglu S, Broemeling LD, Grimm EA, Tari AM. A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide. Mol Cancer Ther. 2002;1:1009-1017.
27. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9- dependent manner. J Cell Biol. 1999;144:281-292.
28. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
29. Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ, et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol. 2002;20:1063-1068.
30. Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene. 2000;19:617-623.
31. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol. 2008;26:5198-5203.
32. Argyriou AA, Giannopoulou E, Kalofonos HP. Angiogenesis and antiangiogenic molecularly targeted therapies in malignant gliomas. Oncology. 2009;77:1-11.
33. Plate KH, Breier G, Weich HA, Mennel HD, Risau W. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer. 1994;59:520-529.
34. Altieri DC. New wirings in the survivin networks. Oncogene. 2008;27:6276-6284.
35. Stauber RH, Mann W, Knauer SK. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res. 2007;67:5999-6002. (Pubitemid 47037475)
36. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46-54.